Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

If you’re looking for trail shoes that are lightweight, flashy, and fun, look no more because the Arc’teryx Vertex Speed ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

The board of directors of AT&T (NYSE:T) today declared a quarterly dividend of $0.2775 per share on the company's common shares. Dividends on the common stock and Series A and Series C preferred stock ...

The forward-looking statements contained in this Press Release are based on the expectations, estimates and projections of management of Vertex as of the date of this Press Release unless ...

He's the Chief Medical Officer for pain research at CenExel. He's also a steering committee member for Vertext Pharmaceuticals.

I examined several types of gum and found that the most common weight of an individual piece of gum is 1.4g – that means that globally, a staggering 2.436 million tonnes of gum are produced each year.

In a regulatory filing, Vertex Pharmaceuticals (VRTX) chief scientific officer David Altshuler disclosed the sale of 3,231 common shares of the company on March 13 at a price of $510 per share.

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

Vertex holds a dominant position in the cystic franchise (“CF”) market. Its CF sales continue to grow, driven by higher sales of Trikafta/Kaftrio in younger age groups. Vertex’s CF product ...